A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 256 participants.

Also called NCT07660796

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 256 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07660796
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07660796. Randomized; double masking; primary purpose treatment. Start 2026-07-06 (anticipated); primary completion 2027-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
Condition
Hypertension
Intervention (Drug)
HCP1803-3
Intervention (Drug)
HCP1803-4
Intervention (Drug)
RLD2001-1
Intervention (Drug)
RLD2001-2
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct07660796
Content hash
7b7f55290f70dc8960549dfdcf036be44f9f9f3351efc14b006a636b00b31817